Bone Biologics Corp [NASDAQ: BBLG] price surged by 8.62 percent to reach at $0.04. The company report on November 15, 2023 at 7:03 AM that BBLG Offers Good Entry Opportunity.
By Brad Sorensen, CFA.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
A sum of 3645578 shares traded at recent session while its average daily volume was at 266.34K shares. Bone Biologics Corp shares reached a high of $0.5431 and dropped to a low of $0.475 until finishing in the latest session at $0.54.
The one-year BBLG stock forecast points to a potential upside of 98.56. The average equity rating for BBLG stock is currently 1.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Bone Biologics Corp [BBLG]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBLG shares is $37.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBLG stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Bone Biologics Corp is set at 0.04 The Price to Book ratio for the last quarter was 0.11, with the Price to Cash per share for the same quarter was set at 1.98.
BBLG Stock Performance Analysis:
Bone Biologics Corp [BBLG] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.70. With this latest performance, BBLG shares dropped by -12.40% in over the last four-week period, additionally sinking by -89.20% over the last 6 months – not to mention a drop of -93.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBLG stock in for the last two-week period is set at 44.87, with the RSI for the last a single of trading hit 53.80, and the three-weeks RSI is set at 39.35 for Bone Biologics Corp [BBLG]. The present Moving Average for the last 50 days of trading for this stock 0.6106, while it was recorded at 0.5162 for the last single week of trading, and 3.9381 for the last 200 days.
Insight into Bone Biologics Corp Fundamentals:
Return on Total Capital for BBLG is now -58.54, given the latest momentum, and Return on Invested Capital for the company is -23.71. Return on Equity for this stock declined to -23.71, with Return on Assets sitting at -19.57.
Reflecting on the efficiency of the workforce at the company, Bone Biologics Corp [BBLG] managed to generate an average of -$742,310 per employee.Bone Biologics Corp’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.69 and a Current Ratio set at 1.69.
Bone Biologics Corp [BBLG] Institutonal Ownership Details
The top three institutional holders of BBLG stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in BBLG stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in BBLG stock with ownership which is approximately 5.7994%.
